The development of effective methods to cryopreserve precious cell types has had tremendous impact on regenerative and transfusion medicine. Hematopoietic stem cell (HSC) transplants from cryopreserved umbilical cord blood (UCB) have been used for regenerative medicine therapies to treat conditions including hematological cancers and immodeficiencies. Red blood cell (RBC) cryopreservation in blood banks extends RBC storage time from 42 days (for
hypothermic storage) to 10 years and can overcome shortages in blood supplies from the high demand of RBC transfusions. Currently, the most commonly utilized cryoprotectants are 10%
dimethyl sulfoxide (DMSO) for UCB and 40% glycerol for RBCs. DMSO is significantly toxic
both to cells and patients upon its infusion. Glycerol must be removed to <1% post-thaw using
complicated, time consuming and expensive deglycerolization procedures prior to transfusion to prevent intravascular hemolysis. Thus, there is an urgent need for improvements in
cryopreservation processes to reduce/eliminate the use of DMSO and glycerol.
Ice recrystallization during cryopreservation is a significant contributor to cellular injury and
reduced cell viability. Compounds capable of inhibiting this process are thus highly desirable as novel cryoprotectants to mitigate this damage. The first compounds discovered that were ice recrystallization inhibitors were the biological antifreezes (BAs), consisting of antifreeze proteins and glycoproteins (AFPs and AFGPs). As such, BAs have been explored as potential cryoprotectants, however this has been met with limited success. The thermal hysteresis (TH)activity and ice binding capabilities associated with these compounds can facilitate cellular damage, especially at the temperatures associated with cryopreservation. Consequently,
compounds that possess “custom-tailored” antifreeze activity, meaning they exhibit the potent ice recrystallization inhibition (IRI) activity without the ability to bind to ice or exhibit TH activity,are highly desirable for potential use in cryopreservation.
This thesis focuses on the rational design of potent ice recrystallization inhibitors and on
elucidating important key structural motifs that are essential for potent IRI activity. While
particular emphasis in on the development of small molecule IRIs, exploration into structural
features that influence the IRI of natural and synthetic BAs and BA analogues is also described as these are some of the most potent inhibitors known to date. Furthermore, this thesis also
investigates the use of small molecule IRIs for the cryopreservation of various different cell types to ascertain their potential as novel cryoprotectants to improve upon current cryopreservation protocols, in particular those used for the long-term storage of blood and blood products.
Through structure-function studies the influence of (glyco)peptide length, glycosylation and
solution structure for the IRI activity of synthetic AFGPs and their analogues is described. This thesis also explores the relationship between IRI, TH and cryopreservation ability of natural
AFGPs, AFPs and mutants of AFPs. While these results further demonstrated that BAs are
ineffective as cryoprotectants, it revealed the potential influence of ice crystal shape and growth progression on cell survival during cryopreservation.
One of the most significant results of this thesis is the discovery of alkyl- and phenolicglycosides as the first small molecule ice recrystallization inhibitors. Prior to this discovery, all reported small molecules exhibited only a weak to moderate ability to inhibit ice recrystallization.
To understand how these novel small molecules inhibit this process, structure-function studies
were conducted on highly IRI active molecules. These results indicated that key structural
features, including the configuration of carbons bearing hydroxyl groups and the configuration of
the anomeric center bearing the aglycone, are crucial for potent activity. Furthermore, studies on the phenolic-glycosides determined that the presence of specific substituents and their position on the aryl ring could result in potent activity. Moreover, these studies underscored the sensitivity of IRI activity to structural modifications as simply altering a single atom or functional group on this substituent could be detrimental for activity.
Finally, various IRI active small molecules were explored for their cryopreservation potential
with different cell types including a human liver cell line (HepG2), HSCs obtained from human
UCB, and RBCs obtained from human peripheral blood. A number of phenolic-glycosides were
found to be effective cryo-additives for RBC freezing with significantly reduced glycerol
concentrations (less than 15%). This is highly significant as it could drastically decrease the
deglycerolization processing times that are required when RBCs are cryopreserved with 40%
glycerol. Furthermore, it demonstrates the potential for IRI active small molecules as novel
cryoprotectants that can improve upon current cryopreservation protocols that are limited in terms of the commonly used cryoprotectants, DMSO and glycerol.
| Identifer | oai:union.ndltd.org:uottawa.ca/oai:ruor.uottawa.ca:10393/30634 |
| Date | January 2014 |
| Creators | Capicciotti, Chantelle |
| Contributors | Ben, Robert |
| Publisher | Université d'Ottawa / University of Ottawa |
| Source Sets | Université d’Ottawa |
| Language | English |
| Detected Language | English |
| Type | Thesis |
Page generated in 0.0112 seconds